Literature DB >> 9223527

Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope.

R B Roden1, A Armstrong, P Haderer, N D Christensen, N L Hubbert, D R Lowy, J T Schiller, R Kirnbauer.   

Abstract

We have determined that three type-specific and conformationally dependent monoclonal antibodies, H16.E70, H16.U4, and H16.V5, neutralize pseudotype human papillomavirus type 16 (HPV16) virions in vitro. H16.U4 and H16.V5 neutralized pseudotype virions derived from the German HPV16 variant 114K and the Zairian variant Z-1194 with equal efficiency. In contrast, neutralization of Z-1194 pseudotype virions by H16.E70 was two orders of magnitude weaker than neutralization of 114K pseudotype virions. This difference correlated with enzyme-linked immunosorbent assay reactivity of H16.E70 to L1 virus-like particles of the two variants. A substitution at residue 282 of L1 was responsible for this differential reactivity, suggesting that this residue constitutes part of the H16.E70 epitope.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9223527      PMCID： PMC191893     

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  34 in total

1.  Neutralization of CRPV infectivity by monoclonal antibodies that identify conformational epitopes on intact virions.

Authors:  N D Christensen; J W Kreider
Journal:  Virus Res       Date:  1991-11       Impact factor: 3.303

Review 2.  Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types.

Authors:  H zur Hausen
Journal:  Curr Top Microbiol Immunol       Date:  1994       Impact factor: 4.291

3.  Antibody-mediated neutralization in vivo of infectious papillomaviruses.

Authors:  N D Christensen; J W Kreider
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

4.  Monoclonal antibody neutralization of BPV-1.

Authors:  N D Christensen; J W Kreider
Journal:  Virus Res       Date:  1993-05       Impact factor: 3.303

5.  Three-dimensional structure of vaccinia virus-produced human papillomavirus type 1 capsids.

Authors:  M E Hagensee; N H Olson; T S Baker; D A Galloway
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

6.  Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic.

Authors:  R Kirnbauer; F Booy; N Cheng; D R Lowy; J T Schiller
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

7.  Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles.

Authors:  R Kirnbauer; J Taub; H Greenstone; R Roden; M Dürst; L Gissmann; D R Lowy; J T Schiller
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

8.  Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden.

Authors:  P Pisani; D M Parkin; J Ferlay
Journal:  Int J Cancer       Date:  1993-12-02       Impact factor: 7.396

9.  Interaction of papillomaviruses with the cell surface.

Authors:  R B Roden; R Kirnbauer; A B Jenson; D R Lowy; J T Schiller
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

10.  Serological differentiation of human papillomavirus types 11, 16 and 18 using recombinant virus-like particles.

Authors:  R C Rose; W Bonnez; C Da Rin; D J McCance; R C Reichman
Journal:  J Gen Virol       Date:  1994-09       Impact factor: 3.891
View more
  49 in total

Review 1.  Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins.

Authors:  Xiao Zhang; Lu Xin; Shaowei Li; Mujin Fang; Jun Zhang; Ningshao Xia; Qinjian Zhao
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Development and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individuals.

Authors:  Joseph G Dauner; Yuanji Pan; Allan Hildesheim; Troy J Kemp; Carolina Porras; Ligia A Pinto
Journal:  Mol Cell Probes       Date:  2012-01-18       Impact factor: 2.365

3.  Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles.

Authors:  Timothy D Culp; Christin M Spatz; Cynthia A Reed; Neil D Christensen
Journal:  Virology       Date:  2007-01-12       Impact factor: 3.616

4.  Multiscale simulation of microbe structure and dynamics.

Authors:  Harshad Joshi; Abhishek Singharoy; Yuriy V Sereda; Srinath C Cheluvaraja; Peter J Ortoleva
Journal:  Prog Biophys Mol Biol       Date:  2011-07-23       Impact factor: 3.667

5.  Human papillomavirus type 16 pseudovirions with few point mutations in L1 major capsid protein FG loop could escape actual or future vaccination for potential use in gene therapy.

Authors:  Maxime J J Fleury; Antoine Touzé; Pierre Coursaget
Journal:  Mol Biotechnol       Date:  2014-05       Impact factor: 2.695

6.  Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine.

Authors:  Joseph G Dauner; Yuanji Pan; Allan Hildesheim; Clayton Harro; Ligia A Pinto
Journal:  Vaccine       Date:  2010-06-17       Impact factor: 3.641

7.  Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particles.

Authors:  Hongtao Zhang; Yujun Huang; Raja Fayad; Gregory T Spear; Liang Qiao
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

8.  A direct comparison of human papillomavirus type 16 L1 particles reveals a lower immunogenicity of capsomeres than viruslike particles with respect to the induced antibody response.

Authors:  Nadja Thönes; Anna Herreiner; Lysann Schädlich; Konrad Piuko; Martin Müller
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

9.  Identification of a human papillomavirus type 16-specific epitope on the C-terminal arm of the major capsid protein L1.

Authors:  Joseph J Carter; Greg C Wipf; Sarah F Benki; Neil D Christensen; Denise A Galloway
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

10.  Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16.

Authors:  Arvind Varsani; Anna-Lise Williamson; Debbie de Villiers; Inga Becker; Neil D Christensen; Edward P Rybicki
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.